The Claim
In human cerebral organoids carrying the APOE4 allele, knockout of RBFOX1 increases phosphorylated tau levels at Ser202/Thr205 and Ser396/Ser404 by approximately 1.5- to 5-fold relative to APOE4 control organoids, without affecting amyloid-beta deposition.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In lab-grown human brain tissue models with the APOE4 gene variant, removing RBFOX1 increases tau protein phosphorylation at specific sites by 1.5 to 5 times compared to models without this removal, while amyloid-beta levels remain unchanged.
See the scientific wording
In human cerebral organoids with the APOE4 allele, RBFOX1 knockout exacerbates tau hyperphosphorylation at Ser202/Thr205 and Ser396/Ser404, increasing phosphorylated tau levels by approximately 1.5- to 5-fold compared to APOE4 controls, without altering amyloid-beta deposition.
When RBFOX1 is missing in brain tissue with the APOE4 gene, immune cells in the brain called microglia form abnormally and become overactive. These overactive microglia release inflammatory chemicals and build up fat inside themselves, which stresses nearby nerve cells. This stress changes the balance of enzymes that add phosphate groups to tau protein, causing too much phosphorylation at specific sites. The excess phosphorylated tau accumulates without affecting amyloid plaques.
What the research says
1 studyIn lab-grown brain tissue with the APOE4 gene, turning off RBFOX1 made toxic tau protein build up 1.5 to 5 times more, but didn’t change the amyloid plaques—exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.